CAR-T cell therapy has been a groundbreaking development in treating lymphoma, offering hope for patients whose cancer hasn't responded to other treatments. It's particularly exciting because it provides a chance of cure for some patients with lymphomas that couldn't be cured through any other treatment method.
The therapy Show Full Answer
CAR-T cell therapy has been a groundbreaking development in treating lymphoma, offering hope for patients whose cancer hasn't responded to other treatments. It's particularly exciting because it provides a chance of cure for some patients with lymphomas that couldn't be cured through any other treatment method.
The therapy works by reprogramming a patient's own T cells to recognize and attack resistant lymphoma cells. This targeted approach is both a form of immunotherapy and targeted therapy. Several CAR-T cell therapies have been approved for treating various types of lymphoma, including:
• Yescarta (Axicabtagene ciloleucel)
• Tecartus (Brexucabtagene autoleucel)
• Breyanzi (Lisocabtagene maraleucel)
• Kymriah (Tisagenlecleucel)
These treatments have shown particular success in treating aggressive NHL, resistant mantle cell lymphoma, and resistant low-grade follicular lymphoma.
September 10, 2025
Join
Your Privacy Choices
